{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:46:15Z","timestamp":1791870375813,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Clinical trials have shown the benefits of lung cancer screening (LCS) in certain high-risk groups using low-dose high-resolution computed tomography (LDCT). Risk groups are usually defined by age and tobacco use. Exposure to asbestos dust is an important occupational risk factor for lung cancer. Since 2014, the German Social Accident Insurance (DGUV) has introduced annual LCS for high-risk groups (EVA-LCS). In addition to occupational asbestos dust exposure, the population at risk is defined by age (\u2265\u200955 years) and tobacco consumption (\u2265\u200930 pack-years). The health services research project EVALUNG aims to evaluate the EVA-LCS using a combination of quantitative and qualitative methods.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The quantitative part will be based on a secondary data analysis of routine administrative and medical data from the EVA-LCS. The results of the individual screening rounds will be analysed in a cross-sectional design. Primary endpoints are participation patterns, the rate of findings requiring further diagnostic investigation, the detection of lung cancer including tumour stage and characteristics, and the notification and recognition of asbestos-related occupational diseases. Secondary endpoints include false-positive and false-negative findings, incidence of other cancers, and all-cause and cancer-related mortality. To avoid selection bias, a complete set of anonymised data (approximately 22,200 individuals as of 12\/2021) from the EVA-LCS will be transmitted for use in EVALUNG. A sub-sample will be used to perform longitudinal analyses and explore a linkage with cancer registry data. Another component is the development and piloting of quality indicators. Qualitative interviews will be conducted to analyse the perceptions, satisfaction, and potential psychological effects of EVA-LCS participants. Interviews with participating physicians will focus on their attitudes and knowledge regarding LCS. A further aim is to develop an evidence-based decision aid.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>The EVALUNG concept is based on various complementary approaches, enabling a comprehensive evaluation of the EVA-LCS and the identification of optimization potentials. The quality of the data is crucial for the validity of the quantitative analyses. One way to address potential limitations is to link the data with cancer registry data. The results may contribute to the planning and development of a national LDCT lung cancer screening programme in Germany.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13690-025-01662-9","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:50:05Z","timestamp":1753876205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of lung cancer early detection offered by the German Social Accident Insurance for formerly asbestos-exposed employees using low-dose computed tomography \u2013 setting and study design"],"prefix":"10.1186","volume":"83","author":[{"given":"Felix","family":"Greiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Heidrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Taeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Wiethege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Harth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"1662_CR1","unstructured":"Robert Koch-Institut, editor und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V, editor: Krebs in Deutschland f\u00fcr 2019\/2020. 14th edition. Berlin; 2023."},{"issue":"10","key":"1662_CR2","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.jtho.2019.05.044","volume":"14","author":"National Lung Screening Trial Research Team","year":"2019","unstructured":"National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial. J Thorac Oncol. 2019;14(10):1732\u201342.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"1662_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","volume":"382","author":"HJ de Koning","year":"2020","unstructured":"de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503\u201313.","journal-title":"N Engl J Med"},{"key":"1662_CR4","doi-asserted-by":"crossref","unstructured":"Hunger T, Wanka-Pail E, Brix G, Griebel J. Lung cancer screening with low- dose CT in smokers: A systematic review and meta-analysis. Diagnostics (Basel). 2021;11(6):1040.","DOI":"10.3390\/diagnostics11061040"},{"issue":"23","key":"1662_CR5","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1200\/JCO.20.02574","volume":"39","author":"F Passiglia","year":"2021","unstructured":"Passiglia F, Cinquini M, Bertolaccini L, Del Re M, Facchinetti F, Ferrara R, Franchina T, Larici AR, Malapelle U, Menis J, et al. Benefits and harms of lung cancer screening by chest computed tomography: A systematic review and meta-analysis. J Clin Oncol. 2021;39(23):2574\u201385.","journal-title":"J Clin Oncol"},{"key":"1662_CR6","doi-asserted-by":"crossref","unstructured":"Bonney A, Malouf R, Marchal C, Manners D, Fong KM, Marshall HM, Irving LB, Manser R. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev 2022(8):Art. No.: CD013829.","DOI":"10.1002\/14651858.CD013829.pub2"},{"issue":"3","key":"1662_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.21037\/tlcr.2018.05.12","volume":"7","author":"PF Pinsky","year":"2018","unstructured":"Pinsky PF. Lung cancer screening with low-dose CT: a world-wide view. Transl Lung Cancer Res. 2018;7(3):234\u201342.","journal-title":"Transl Lung Cancer Res"},{"key":"1662_CR8","volume-title":"A review of human carcinogens. Volume 100C: arsenic, metals, fibres, and dusts","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2012","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. A review of human carcinogens. Volume 100\u00a0C: Arsenic, metals, fibres, and dusts. Lyon: International Agency for Research on Cancer; 2012."},{"issue":"3","key":"1662_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/bjc.2011.563","volume":"106","author":"V McCormack","year":"2012","unstructured":"McCormack V, Peto J, Byrnes G, Straif K, Boffetta P. Estimating the asbestos-related lung cancer burden from mesothelioma mortality. Br J Cancer. 2012;106(3):575\u201384.","journal-title":"Br J Cancer"},{"key":"1662_CR10","doi-asserted-by":"crossref","unstructured":"Klebe S, Leigh J, Henderson DW, Nurminen M. Asbestos, smoking and lung cancer: an update. Int J Environ Res Public Health. 2019;17(1):258.","DOI":"10.3390\/ijerph17010258"},{"issue":"6","key":"1662_CR11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1378\/chest.13-2181","volume":"145","author":"M Ollier","year":"2014","unstructured":"Ollier M, Chamoux A, Naughton G, Pereira B, Dutheil F. Chest CT scan screening for lung cancer in asbestos occupational exposure: a systematic review and meta-analysis. Chest. 2014;145(6):1339\u201346.","journal-title":"Chest"},{"key":"1662_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2019.03.003","volume":"131","author":"P Maisonneuve","year":"2019","unstructured":"Maisonneuve P, Rampinelli C, Bertolotti R, Misotti A, Lococo F, Casiraghi M, Spaggiari L, Bellomi M, Novellis P, Solinas M, et al. Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos. Lung Cancer. 2019;131:23\u201330.","journal-title":"Lung Cancer"},{"issue":"8","key":"1662_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/oem.2008.041525","volume":"66","author":"B Clin","year":"2009","unstructured":"Clin B, Morlais F, Guittet L, Gislard A, Marquignon MF, Paris C, Caillard JF, Launoy G, Letourneux M. Performance of chest radiograph and CT scan for lung cancer screening in asbestos-exposed workers. Occup Environ Med. 2009;66(8):529\u201334.","journal-title":"Occup Environ Med"},{"issue":"6","key":"1662_CR14","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/ije\/dyy212","volume":"47","author":"F Barbone","year":"2018","unstructured":"Barbone F, Barbiero F, Belvedere O, Rosolen V, Giangreco M, Zanin T, Pisa FE, Meduri S, Follador A, Grossi F, et al. Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers. Int J Epidemiol. 2018;47(6):1981\u201391.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"1662_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijheh.2009.09.001","volume":"213","author":"B Pesch","year":"2010","unstructured":"Pesch B, Taeger D, Johnen G, Gross IM, Weber DG, Gube M, M\u00fcller-Lux A, Heinze E, Wiethege T, Neumann V, et al. Cancer mortality in a surveillance cohort of German males formerly exposed to asbestos. Int J Hyg Environ Health. 2010;213(1):44\u201351.","journal-title":"Int J Hyg Environ Health"},{"issue":"1","key":"1662_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jtho.2020.10.127","volume":"16","author":"J Sands","year":"2021","unstructured":"Sands J, Tammem\u00e4gi MC, Couraud S, Baldwin DR, Borondy-Kitts A, Yankelevitz D, Lewis J, Grannis F, Kauczor HU, von Stackelberg O, et al. Lung screening benefits and challenges: A review of the data and outline for implementation. J Thorac Oncol. 2021;16(1):37\u201353.","journal-title":"J Thorac Oncol"},{"issue":"1133","key":"1662_CR17","doi-asserted-by":"publisher","first-page":"20200260","DOI":"10.1259\/bjr.20200260","volume":"95","author":"M Silva","year":"2022","unstructured":"Silva M, Milanese G, Ledda RE, Nayak SM, Pastorino U, Sverzellati N. European lung cancer screening: valuable trial evidence for optimal practice implementation. Br J Radiol. 2022;95(1133):20200260.","journal-title":"Br J Radiol"},{"key":"1662_CR18","unstructured":"National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)\u2013 Lung Cancer Screening. Version 1.2022\u2013 October 26. 2021. 2021."},{"key":"1662_CR19","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Langversion 2.2, 2023, AWMF-Registernummer: 020\/007OL. 2023. Accessed 02 Jun 2025. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/lungenkarzinom"},{"issue":"6","key":"1662_CR20","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00330-020-06727-7","volume":"30","author":"HU Kauczor","year":"2020","unstructured":"Kauczor HU, Baird AM, Blum TG, Bonomo L, Bostantzoglou C, Burghuber O, \u010cepick\u00e1 B, Comanescu A, Couraud S, Devaraj A, et al. ESR\/ERS statement paper on lung cancer screening. Eur Radiol. 2020;30(6):3277\u201394.","journal-title":"Eur Radiol"},{"key":"1662_CR21","unstructured":"Duell M, Wiethege T. Das erweiterte Vorsorgeangebot (EVA) zur Lungenkrebsfr\u00fcherkennung \u2013 Update 2019. DGUV Forum. 2020;(1):15\u20137."},{"key":"1662_CR22","unstructured":"Bundesamt f\u00fcr Strahlenschutz (BfS). Lungenkrebsfr\u00fcherkennung mittels Niedrigdosis-Computertomographie - Wissenschaftliche Bewertung des Bundesamtes f\u00fcr Strahlenschutz gem\u00e4\u00df \u00a7 84 Absatz 3 Strahlenschutzgesetz (BfS-34\/21). Salzgitter; 2021."},{"key":"1662_CR23","unstructured":"DGUV Vorsorge: Konzept zur radiologischen Qualit\u00e4tssicherung (Stand: 03.2021). 2021. https:\/\/gvs.bgetem.de\/erweitertes-vorsorgeangebot-zur-frueherkennung-von-lungenkrebs\/konzept-zur-radiologischen-qualitaetssicherung. Accessed 02 Jun 2025."},{"key":"1662_CR24","unstructured":"Arnold F, Centmayer A, Klinkhammer S, Perleberg Y, Wiethege T. Nachgehende Vorsorge \u2013 digitales Meldeportal DGUV Vorsorge. DGUV Forum. 2022;(3):34\u20136."},{"issue":"06","key":"1662_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1055\/s-0043-110156","volume":"189","author":"AG DRauE","year":"2017","unstructured":"AG DRauE. Protokollempfehlungen der AG DRauE zur Durchf\u00fchrung von Low-Dose-Volumen-HRCT-Untersuchungen der Lunge. Rofo. 2017;189(06):553\u201367.","journal-title":"Rofo"},{"issue":"5","key":"1662_CR26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00103-021-03475-x","volume":"65","author":"I Pigeot","year":"2022","unstructured":"Pigeot I, Bongaerts B, Eberle A, Katalinic A, Kieschke J, Luttmann S, Meyer M, Nennecke A, Rathmann W, Stabenow R, et al. [Linkage of claims data with data from epidemiological cancer registries: possibilities and limitations in the German federal states]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022;65(5):615\u201323.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"8\u20139","key":"1662_CR27","first-page":"e84","volume":"74","author":"H Kaj\u00fcter","year":"2012","unstructured":"Kaj\u00fcter H, Batzler WU, Krieg V, Heidinger O, Hense HW. [Linkage of secondary data with cancer registry data on the basis of encrypted personal identifiers - results from a pilot study in North Rhine-Westphalia]. Gesundheitswesen. 2012;74(8\u20139):e84\u201389.","journal-title":"Gesundheitswesen"},{"key":"1662_CR28","unstructured":"German Guideline Program in Oncology (GGPO) of the German Cancer Society, German Cancer Aid and the Association of the Scientific Medical Societies in Germany: Development of guideline-based quality indicators. Methodology for the German Guideline Program in Oncology, Version 3.0. 2021. https:\/\/www.leitlinienprogramm-onkologie.de\/methodik\/grundlegende-informationen-zur-methodik. Accessed 02 Jun 2025."},{"key":"1662_CR29","volume-title":"Hospital-Wide quality assurance: models for implementation and development","author":"C Wilson","year":"1987","unstructured":"Wilson C. Hospital-wide quality assurance: models for implementation and development. Toronto: W.B. Saunders; 1987."},{"issue":"3","key":"1662_CR30","doi-asserted-by":"publisher","first-page":"e4705","DOI":"10.1371\/journal.pone.0004705","volume":"4","author":"G Elwyn","year":"2009","unstructured":"Elwyn G, O\u2019Connor AM, Bennett C, Newcombe RG, Politi M, Durand MA, Drake E, Joseph-Williams N, Khangura S, Saarimaki A, et al. Assessing the quality of decision support technologies using the international patient decision aid standards instrument (IPDASi). PLoS ONE. 2009;4(3):e4705.","journal-title":"PLoS ONE"},{"issue":"11","key":"1662_CR31","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1055\/a-0998-4399","volume":"191","author":"D Wormanns","year":"2019","unstructured":"Wormanns D, Kauczor H-U, Antoch G, Biederer J, Herth FJF, Vogel-Claussen J, Reinmuth N, Pfeifer M. Joint statement of the German radiological society and the German respiratory society on a quality-assured early detection program for lung cancer with low-dose CT. Rofo. 2019;191(11):993\u20137.","journal-title":"Rofo"},{"key":"1662_CR32","doi-asserted-by":"publisher","DOI":"10.1055\/a-2594-5102","author":"H Keller","year":"2025","unstructured":"Keller H, Greiner F, Heidrich J, Harth V. [Development and pilot testing of a decision aid for early detection of lung cancer with low-dose CT offered to formerly asbestos-exposed employees]. Pneumologie. 2025. https:\/\/doi.org\/10.1055\/a-2594-5102. Online ahead of print.","journal-title":"Pneumologie"},{"issue":"1","key":"1662_CR33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/a-2175-4580","volume":"78","author":"TG Blum","year":"2024","unstructured":"Blum TG, Vogel-Claussen J, Andreas S, Bauer TT, Barkhausen J, Harth V, Kauczor HU, Pankow W, Welcker K, Kaaks R, et al. [Statement paper on the implementation of a national organized program in Germany for the early detection of lung cancer in risk populations using low-dose CT screening including management of screening findings]. Pneumologie. 2024;78(1):15\u201334.","journal-title":"Pneumologie"}],"container-title":["Archives of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-025-01662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13690-025-01662-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-025-01662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:41:54Z","timestamp":1757317314000},"score":1,"resource":{"primary":{"URL":"https:\/\/archpublichealth.biomedcentral.com\/articles\/10.1186\/s13690-025-01662-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1662"],"URL":"https:\/\/doi.org\/10.1186\/s13690-025-01662-9","relation":{},"ISSN":["2049-3258"],"issn-type":[{"value":"2049-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The quantitative study components of EVALUNG have been approved by the Ethics Committee of the Hamburg Medical Association (reference number 2022-100917-BO-ff). Informed consent is not required for secondary use of anonymised data from the EVA-LCS. The data protection concept and the associated anonymisation concept have been approved by the responsible data protection officers of the GVS, DGUV and participating UVT. Linkage to cancer registry data is still under development and subject to approval by the relevant committees and authorities. Participation in the qualitative interviews is voluntary for screening-participants and physicians. Informed consent will be obtained in advance. The qualitative study was approved by the Local Psychological Ethics Committee of the Centre for Psychosocial Medicine at the University Medical Centre Hamburg-Eppendorf (reference number LPEK-0589).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VH declares the following COI: He is Director of the Institute for Occupational and Maritime Medicine (ZfAM). In the outpatient clinic of the ZfAM, preventive health care examinations and counselling on LDCT according to EVA-LCS are carried out. As head of the Scientific Advisory Board of EVA-LCS, he is reimbursed for travel and expenses. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}